SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Estimated average burden hours per 0.5 response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A Chang Ca	* 2. Date o Requiring (Month/D 06/23/2	g Statement ay/Year)	tatement (Year) Monte Rosa Therapeutics, Inc. [GLUE]							
(Last) 2855 SAND			4. Relationship of Report Issuer (Check all applicable)	с ,			5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Street) MENLO PARK	CA 94025			Director Officer (give title below)	X 10% C Other below	(specify		eck Applicable Form filed b Person	y One Reporting y More than One	
(City)	(State) (Zip)									
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Inst 4)	r. Form: I (D) or I			4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned(e.g., puts, calls, warrants, options, convertible securities)										
E) (M		2. Date Exerce Expiration Da (Month/Day/)	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of		5. Ownership Form:	6. Nature of Indirect Beneficial Ownorship (Instr	
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivat	ive	Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)	
Series A-2 co stock	onvertible preferred	(1)	(1)	Common Stock	2,715,968	(1)		Ι	See Note 2 ⁽²⁾	
Series B con	vertible preferred stock	(1)	(1)	Common Stock	3,257,328	(1)		I	See Note 2 ⁽²⁾	
Series C convertible preferred stock		(1)	(1)	Common Stock	669,002	(1)		Ι	See Note 2 ⁽²⁾	

Explanation of Responses:

1. Each share of Series A-2 convertible preferred stock, Series B convertible preferred stock and Series C convertible preferred stock (collectively, the "Preferred Stock") is convertible into shares of the Issuer's Common Stock on a 3.5305-for-one basis. Upon the closing of the Issuer's initial public offering, all shares of Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.

2. The Reporting Person is a manager of NEA 17 GP, LLC ("NEA 17 GP"), which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Remarks:

<u>/s/ Sasha Keough,</u> <u>attorney-in-fact</u>

06/23/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.